AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30361296
Drug: Levodopa/carbidopa slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa slow-release formulation after 12 weeks
Trial: 30361296
Drug: Control groups
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control groups (medicated and drug-naive)
Trial: 30361296
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist withdrawal syndrome
Trial: 30361875
Drug: Metronomic capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic capecitabine 500 mg PO TID (could be reduced to 500 mg QD) and exemestane 25 mg QD or letrozole 2.5 mg QD
Trial: 30361875
Drug: Metronomic capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic capecitabine combined with aromatase inhibitors
Trial: 30362288
Drug: Recombinant von
RxNorm normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein Injection [Altuviiio]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant von Willebrand factor (rVWF) administered alone
Trial: 30362948
Drug: Drug use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug use during sex reported (n = 6)
Trial: 30363894
Drug: l-tyrosine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-tyrosine 1,000 mg (500 mg 2× daily) for 7 days
Trial: 30364428
Drug: VRC01 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01 (40 mg/kg)
Trial: 30365452
Drug: TDF/FTC +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC + DRV/r (once daily; 4 pills/day)
Trial: 30365452
Drug: RAL +
RxNorm normalized name: Hydrocortisone Acetate/Lidocaine Hydrochloride 1%-5% Topical application Lotion [DERMACINRX LIDOTRAL + HYDROCORTISONE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAL + DRV/r (twice daily; 5 pills/day)
Trial: 30366567
Drug: 1% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% testosterone gel daily for 12 months
Trial: 30366567
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel daily for 12 months
Trial: 30366774
Drug: Increased daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased daily portion of fruits and vegetables
Trial: 30368548
Drug: Piperacillin/tazobactam (4/0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (4/0.5 g, tid) administered over 0.5 h
Trial: 30370457
Drug: Aquablation for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquablation for <100 cc prostates
Trial: 30370457
Drug: Aquablation for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquablation for >100 cc prostates
Trial: 30370468
Drug: Tocilizumab monotherapy
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab monotherapy (8 mg/kg)
Trial: 30370468
Drug: Tocilizumab combined
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab combined with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)
Trial: 30371223
Drug: Warfarin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin with SSRIs
Trial: 30373683
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure control with medications
Trial: 30373800
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) with limited sampling strategies (LSSs)
Trial: 30374686
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg, every 2 weeks) with temsirolimus (25 mg weekly)
Trial: 30377191
Drug: Oral Carnitine
RxNorm normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Carnitine Challenge Test (OCCT)
Trial: 30377537
Drug: Hatha yoga,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hatha yoga, implemented via twice weekly 60-min group-based classes for 12 weeks.
Trial: 30377677
Drug: ω-3 supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 supplement use
Trial: 30380032
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care STEMI treatment including DAPT
Trial: 30380386
Drug: Hu5F9-G4 (5F9)
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hu5F9-G4 (5F9) antibody with rituximab
Trial: 30381282
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements (protein isolate powder, immunomodulation solution, carbohydrate loading)
Trial: 30382017
Drug: D2-receptor availability
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2-receptor availability assessment
Trial: 30382850
Drug: Ceramic implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceramic implants (PURE Ceramic Implant, Institut Straumann AG, Basel, Switzerland) with a diameter of 4.1 mm
Trial: 30383140
Drug: Imatinib, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib, 400 mg once daily, orally for 5 years
Trial: 30383777
Drug: Benznidazole treatment
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benznidazole treatment (TrG)
Trial: 30384320
Drug: Post-commitment medication
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-commitment medication treatment
Trial: 30385437
Drug: Antihyperglycaemic medication
RxNorm normalized name: ANTIHYPOGLYCEMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihyperglycaemic medication
Trial: 30386824
Drug: MRgRT dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRgRT dose adaptation
Trial: 30387050
Drug: Early 7-day
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early 7-day supplemental parenteral nutrition (SPN)
Trial: 30388108
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 400 mg albendazole (ALB)
Trial: 30389646
Drug: Monthly motivational
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly motivational phone calls by a trained nutritionist and weekly tailored text messages over a 12-month period (high intervention uptake)
Trial: 30389649
Drug: Online integrated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online integrated treatment (8 weeks, 12 modules based on cognitive behavioral therapy and motivational interviewing)
Trial: 30389649
Drug: Psychoeducational control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational control group (links to resources, access to full treatment after follow-up)
Trial: 30390672
Drug: Anti-TNF-α treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-α treatment pre-operatively (n=18)
Trial: 30391776
Drug: Vitamin K-antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K-antagonist (VKA)
Trial: 30391805
Drug: Insulin receptor-related
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin receptor-related genes and dopamine regulation-related genes in the dlPFC
Trial: 30391805
Drug: Insulin receptor-related
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin receptor-related genes and dopamine regulation-related genes in the hippocampus
Trial: 30391805
Drug: Insulin receptor
RxNorm normalized name: Insulin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin receptor gene (INSR)
Trial: 30391805
Drug: Insulin receptor
RxNorm normalized name: Insulin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin receptor substrate 1 and 2
Trial: 30392735
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral ondansetron
Trial: 30392813
Drug: Conventional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies (maximal surgical resection followed by adjuvant craniospinal irradiation and chemotherapy)
Trial: 30393106
Drug: Glecaprevir/pibrentasvir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir/pibrentasvir (300 mg/120 mg) orally once daily for 8 weeks (for patients without cirrhosis) or 12 weeks (for patients with compensated cirrhosis)
Trial: 30394678
Drug: Long-term combined
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term combined antiretroviral therapy (ART)
Trial: 30395220
Drug: Inadequate perioperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inadequate perioperative prophylaxis in patients with established antibiotic treatment
Trial: 30396014
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (H SC) 600 mg via handheld syringe
Trial: 30396014
Drug: Subcutaneous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous trastuzumab (H SC) 600 mg via single-use injection device
Trial: 30396865
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg per day) added to simvastatin (40 mg per day)
Trial: 30397066
Drug: Efavirenz-based antiretroviral
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz-based antiretroviral therapy without any efavirenz dose adjustments in children with TB/HIV coinfection.
Trial: 30397066
Drug: Efavirenz-based antiretroviral
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz-based antiretroviral therapy without any efavirenz dose adjustments in children without TB.
Trial: 30397067
Drug: WCK 5222
RxNorm normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WCK 5222 (Cefepime-Zidebactam Combination)
Trial: 30398516
Drug: Higher baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher baseline sex hormone-binding globulin (SHBG) level among men
Trial: 30398516
Drug: Sex steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex steroids
Trial: 30400780
Drug: Ixazomib in
RxNorm normalized name: Product containing ixazomib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib in combination with carboplatin
Trial: 30400834
Drug: Vaccine acceptance
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine acceptance predictors
Trial: 30400864
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate sodium 70 mg plus vitamin D3 5600 IU once weekly for 26 weeks
Trial: 30402565
Drug: Immediate compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate compression (weekly two-component compression bandages during chemotherapy)
Trial: 30402565
Drug: Delayed compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed compression (compression after chemotherapy)
Trial: 30402678
Drug: Temsirolimus (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (20 mg or 25 mg IV weekly) + Bevacizumab (10 mg/kg every 2 weeks)
Trial: 30403300
Drug: Cidofovir and
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cidofovir and intravenous immunoglobulin
Trial: 30405743
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba pills
Trial: 30408135
Drug: Total bilirubin
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total bilirubin ≥ 40 μmol/L
Trial: 30408135
Drug: Leucocyte count
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucocyte count above 7x10(9)/L
Trial: 30410313
Drug: Filgrastim (Nivestim™)
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim (Nivestim™) administered at home
Trial: 30410448
Drug: Moxonidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.2 mg daily initially, up titrated to 0.4 mg daily in 2 weeks)
Trial: 30410720
Drug: Temsirolimus (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (20 mg/m)
Trial: 30410781
Drug: domperidone (14-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: domperidone (14-day treatment)
Trial: 30411246
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of hydroxyethyl starch (HES) solutions
Trial: 30413378
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP1)
Trial: 30413378
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP2-5)
Trial: 30413378
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP2-3A)
Trial: 30413378
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP3B)
Trial: 30413378
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP4-5)
Trial: 30413378
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (all patients)
Trial: 30413396
Drug: ASP8232 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP8232 40 mg orally once daily for 12 weeks
Trial: 30413396
Drug: ASP8232 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP8232 40 mg
Trial: 30413669
Drug: MBC-11 (0.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBC-11 (0.5-10 mg/kg per day, administered daily for 5 days of every 4 weeks for up to four cycles)
Trial: 30413837
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg everolimus once daily + 50 mg CTX once daily
Trial: 30414054
Drug: micro-fluid challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: micro-fluid challenge (micro-FC; rapid central infusion of 50 ml)
Trial: 30414054
Drug: traditional fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: traditional fluid challenge (FC; 5 ml/kg)
Trial: 30414302
Drug: Decision to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decision to reintroduce antiplatelet therapy
Trial: 30415451
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) 50 mg subcutaneously (SC) monthly
Trial: 30416770
Drug: Leukocyte levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte levels >10.5×10^9/L
Trial: 30416787
Drug: Lung protective
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung protective strategy with low tidal volume (Vt) (≤8 mL/kg) and limitation of the plateau pressure (Pplat) (≤30 cmH2O)
Trial: 30418357
Drug: Anidulafungin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anidulafungin (3 mg/kg on day 1, 1.5 mg/kg daily thereafter for 10-35 days)
Trial: 30418358
Drug: Preferred site
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred site for vaccine administration among HCPs
Trial: 30418539
Drug: Oral broad-spectrum
RxNorm normalized name: Sentinel Spectrum Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral broad-spectrum antibiotics (ciprofloxacin, vancomycin, and metronidazole) for 7 days
Trial: 30419887
Drug: Hydration therapy
RxNorm normalized name: Neosporin Daily Hydration Therapy SPF 20 Lip Balm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration therapy (drinking at least 2 L/day of hypotonic, oligomineral water low in sodium and minerals for at least 12 months)
Trial: 30420883
Drug: 3.0 g IVMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g IVMP (1.0 g/day for 3 consecutive days) in DON (B1)
Trial: 30420883
Drug: IVMP in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVMP in every week schedule (cumulative dose 4.5 g) in GO (A3)
Trial: 30421265
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment for uncomplicated appendicitis
Trial: 30423055
Drug: Age and
RxNorm normalized name: wound drainage and fistula management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age and Sequential Organ Failure Assessment Scores
Trial: 30423165
Drug: Non-recommended rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Non-recommended rivaroxaban doses
Trial: 30423165
Drug: Recommended rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recommended rivaroxaban doses
Trial: 30425161
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment for left-sided stroke
Trial: 30425161
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment for right-sided stroke
Trial: 30425843
Drug: S-1 (80-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (80-120 mg/day on days 1-28 every 42 days, four courses)
Trial: 30425843
Drug: UFT/LV (UFT:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT/LV (UFT: 300-600 mg/day and LV: 75 mg/day on days 1-28 every 35 days, five courses)
Trial: 30426067
Drug: Long-chain n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-chain n-3 polyunsaturated fatty acids (1.5 g docosahexaenoic acid + eicosapentaenoic acid daily) and cocoa flavan-3-ols (500 mg n-3 FLAV daily)
Trial: 30427584
Drug: Rucaparib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 600 mg b.i.d.
Trial: 30427594
Drug: Fluticasone furoate/umeclidinium/vilanterol
RxNorm normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg
Trial: 30427836
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplantation (FMT) administered via gastroscope to the descending part of the duodenum.
Trial: 30428832
Drug: Clinical, neuropsychological,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical, neuropsychological, neuroimaging, and biological markers assessment
Trial: 30428931
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cell infusion
Trial: 30429112
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity treatment with social support
Trial: 30431498
Drug: Decrease of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease of BuChE activity by 100 U/L
Trial: 30431498
Drug: Increase of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase of AChE activity by 1 U/g of hemoglobin
Trial: 30431500
Drug: Intra-operative colloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative colloid administration
Trial: 30442260
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion (VE) of 10 ml/kg
Trial: 30442502
Drug: GSK2857916 (3.40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2857916 (3.40 mg/kg) administered through 1 h intravenous infusions once every 3 weeks (part 2)
Trial: 30442502
Drug: GSK2857916 (0.03-4.60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2857916 (0.03-4.60 mg/kg) administered through 1 h intravenous infusions once every 3 weeks (part 1)
Trial: 30443549
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied sensors for assessing the quality of 18F-FDG injections